化脓性汗腺炎(HS)是一种预后不良的疾病,经常被误解为感染,在所有评估的皮肤病中,对患者生活质量的影响最大。这项研究的主要目的是比较目前可用于治疗HS的各种治疗干预措施。HS的发病机制尚不清楚,但它主要是多因素的,涉及许多因素,如遗传因素,雄激素,局部免疫,微生物,吸烟,和肥胖。尽管关于其有效性的证据有限,通常使用局部抗生素和防腐剂。由于HS病变形成的窦道中细菌定植和生物膜的存在,全身性抗生素通常被用作治疗的主要形式。在经历月经耀斑或显示多囊卵巢综合征症状的HS女性中,激素剂通常被认为是可行和有效的治疗选择。目前,食品和药物管理局和欧洲药品管理局批准的解决中度至重度HS的唯一治疗方法是阿达木单抗,一种靶向肿瘤坏死因子α的抗体.治疗HS的许多外科手术旨在通过消除受影响的毛囊皮脂腺单位来解决炎症。窦道,和相关的碎片阻碍进一步的发展和疤痕。HS继续构成相当大的治疗挑战,需要为患者提供全面的治疗方法。然而,大多数这些治疗的现有证据是有限的,这表明需要进行更广泛的研究,以确定管理HS的最有效干预措施。
Hidradenitis suppurativa (HS) is a disease with a poor prognosis, often misinterpreted as an infection, with the highest impact on the patient\'s quality of life among all the assessed dermatological diseases. The main aim of this study was to compare various therapeutic interventions that are currently available for the treatment of HS. The pathogenesis of HS is not well understood, but it is mostly multifactorial involving a number of factors like genetic factors, androgens, local immunity, microflora, smoking, and obesity. Despite limited evidence on their effectiveness, topical antibiotics and antiseptics are commonly employed. Due to the colonization of bacteria and the presence of biofilms in the sinus tracts formed by HS lesions, systemic antibiotics are commonly employed as the primary form of therapy. In females with HS who experience menstrual flares or display symptoms of polycystic ovary syndrome, hormonal agents are often considered to be a viable and effective therapeutic option. At present, the sole treatment approved by both the Food and Drug Administration and the European Medicines Agency for addressing moderate to severe HS is adalimumab, an antibody that targets tumor necrosis factor alpha. Many surgical procedures in the management of HS aim to address inflammation by eliminating the affected folliculo-pilosebaceous unit, sinus tracts, and associated debris to impede further progression and scarring. HS continues to pose a considerable treatment challenge, necessitating a comprehensive approach for patients. However, the available evidence for most of these treatments is limited, indicating the need for more extensive research to identify the most effective interventions for managing HS.